285 related articles for article (PubMed ID: 31807952)
1. The catecholaldehyde hypothesis: where MAO fits in.
Goldstein DS
J Neural Transm (Vienna); 2020 Feb; 127(2):169-177. PubMed ID: 31807952
[TBL] [Abstract][Full Text] [Related]
2. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
Goldstein DS
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133
[TBL] [Abstract][Full Text] [Related]
3. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
[TBL] [Abstract][Full Text] [Related]
4. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
J Pharmacol Exp Ther; 2016 Feb; 356(2):483-92. PubMed ID: 26574516
[TBL] [Abstract][Full Text] [Related]
6. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
[TBL] [Abstract][Full Text] [Related]
7. The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases.
Goldstein DS
Semin Neurol; 2020 Oct; 40(5):502-514. PubMed ID: 32906170
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
Jinsmaa Y; Isonaka R; Sharabi Y; Goldstein DS
J Pharmacol Exp Ther; 2020 Feb; 372(2):157-165. PubMed ID: 31744850
[TBL] [Abstract][Full Text] [Related]
9. The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein.
Jinsmaa Y; Cooney A; Sullivan P; Sharabi Y; Goldstein DS
Neurosci Lett; 2015 Mar; 590():134-7. PubMed ID: 25637699
[TBL] [Abstract][Full Text] [Related]
10. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.
Jinsmaa Y; Florang VR; Rees JN; Anderson DG; Strack S; Doorn JA
Chem Res Toxicol; 2009 May; 22(5):835-41. PubMed ID: 19388687
[TBL] [Abstract][Full Text] [Related]
11. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Sharabi Y; Mash DC
Parkinsonism Relat Disord; 2015 Jun; 21(6):567-72. PubMed ID: 25829070
[TBL] [Abstract][Full Text] [Related]
12. 3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
Neurochem Res; 2016 Sep; 41(9):2173-8. PubMed ID: 27220335
[TBL] [Abstract][Full Text] [Related]
13. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate.
Rees JN; Florang VR; Anderson DG; Doorn JA
Chem Res Toxicol; 2007 Oct; 20(10):1536-42. PubMed ID: 17887726
[TBL] [Abstract][Full Text] [Related]
14. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.
Goldstein DS; Kopin IJ; Sharabi Y
Pharmacol Ther; 2014 Dec; 144(3):268-82. PubMed ID: 24945828
[TBL] [Abstract][Full Text] [Related]
15. Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones.
Legros H; Janin F; Dourmap N; Bonnet JJ; Costentin J
J Neurosci Res; 2004 Feb; 75(3):429-35. PubMed ID: 14743456
[TBL] [Abstract][Full Text] [Related]
16. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.
Burke WJ; Kumar VB; Pandey N; Panneton WM; Gan Q; Franko MW; O'Dell M; Li SW; Pan Y; Chung HD; Galvin JE
Acta Neuropathol; 2008 Feb; 115(2):193-203. PubMed ID: 17965867
[TBL] [Abstract][Full Text] [Related]
17. The heart of PD: Lewy body diseases as neurocardiologic disorders.
Goldstein DS; Sharabi Y
Brain Res; 2019 Jan; 1702():74-84. PubMed ID: 29030055
[TBL] [Abstract][Full Text] [Related]
18. Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein.
Jinsmaa Y; Sullivan P; Gross D; Cooney A; Sharabi Y; Goldstein DS
Neurosci Lett; 2014 May; 569():27-32. PubMed ID: 24670480
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
Florang VR; Rees JN; Brogden NK; Anderson DG; Hurley TD; Doorn JA
Neurotoxicology; 2007 Jan; 28(1):76-82. PubMed ID: 16956664
[TBL] [Abstract][Full Text] [Related]
20. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]